Jocelyn Solis-Moreira

Feature Writer

B.Sc. Integrative Neuroscience, M.Sc. Psychology

Jocelyn Solis-Moreira graduated with a Bachelor's in Integrative Neuroscience, where she then pursued graduate research looking at the long-term effects of adolescent binge drinking on the brain's neurochemistry in adulthood. She is adept at translating and summarizing complex study findings in all medical fields with a particular interest in neurodegenerative diseases, cancer research, infectious diseases, and public health. As a freelance writer, her work spans from news articles and feature articles to evergreen explainers across many publications. Her overall goal is to make science accessible for all.

Articles from Jocelyn

A new SARS-CoV-2 variant (HMN.19B) has been identified in France

New research published in the Centers for Disease Control and Prevention’s journal Emerging Infectious Diseases has confirmed the emergence of a new SARS-CoV-2 variant called HMN.19B from the viral clade 19B in France. The 19B viral clade — which includes the D614G variant — was prevalent in late 2019 but had since been rarely observed since early 2020 because of newer viral clades.

3 May 2021

Vaccine candidate targeting SARS-CoV-2 nucleocapsid protein elicits protective immune response in animal model

New preclinical results from a study led by David Masopust of the University of Minnesota in Minneapolis, USA, show that a Had5-based vaccine targeting the nucleocapsid protein can also elicit a protective immune response.

3 May 2021

Study finds one-third of COVID-19 patients experience neurological symptoms

The research on the short and long-term effects of COVID-19 disease is ongoing. Still, scientists have found severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affects the brain causing loss of smell and taste, dizziness, muscle pain, fatigue, and other cognitive impairments. However, it remained unknown why certain people developed neurological symptoms while others did not.

3 May 2021

Study estimates true number of COVID-19 deaths by U.S. county

Every country has been affected by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that has spawned a pandemic. For several factors, the United States has been hit hard by the number of coronavirus cases and death. The country currently leads the world with over 32.4 million infections and more than 577,000 COVID-19 deaths.

3 May 2021

Scientists design 'smart' cellular biosensors for detecting SARS-CoV-2 spike

New research led by Hana El-Samad of the University of California, San Francisco, and the Chan-Zuckerberg Biohub confirmed the beneficial use of an antiviral therapeutic called SARSNotch, which uses a combination of the SynNotch platform and de-novo designed protein binders. SARSNotch uses sentinel T cells to detect and mount a genetic response toward the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein.

28 Apr 2021

Why do we lose our sense smell/taste with COVID?

The angiotensin-converting enzyme 2 (ACE2) enzyme attached to the membranes of cells is the entry point for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). They are abundantly found all over the body and most prominently in the lungs and nose.

28 Apr 2021

Study identifies mechanism behind SARS-CoV-2 viral protein production

A new study from German researchers examines how SARS viruses, including the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), hijack cells and reprogram them to enhance viral replication.

27 Apr 2021

First cases of B.1.1.7 variant with E484K mutation in Pennsylvania

The E484K mutation has also been found on the B.1.351 and P.1 variant, contributing to their status as variants of concern. In February 2021, Public Health England published a report of 11 B.1.1.7 genomes that also had the E484K spike mutation. Currently, there are 247 isolates of B.1.1.7 + E484K reported globally, and new research finds the first reports of it in southeastern Pennsylvania.

27 Apr 2021

Real-world study in India finds COVISHIELD vaccine safe and effective

New research led by Naresh Trehan of Medanta-The Medicity in India found the COVISHIELD (ChAdOx1 nCoV-19 Corona Virus Vaccine) vaccine produced an immune response from the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) two weeks after vaccination with limited side effects.

26 Apr 2021

SARS-CoV-2 limits type I and type III IFN protein biogenesis

New research led by Roy Parker of the University of Colorado Boulder finds that SARS-CoV-2 prevents the IFN response despite an increased presence of IFN-encoding mRNAs by suppressing transcriptional processes. Inhibition of IFN mRNAs triggers degradation from the activation of RNase L and the SARS-CoV-2 protein Nsp1.

26 Apr 2021